Publika - Scientific publications from Oslo University Hospital

RSS feed RSS

Publications from OUS - Clinical Addiction Research

207 publications found

Publications 2022

Bukten A, Lokdam NT, Skjærvø I, Ugelvik T, Skurtveit S, Gabrhelík R, Skardhamar T, Lund IO, Havnes IA, Rognli EB, Chang Z, Fazel S, Friestad C, Hesse M, Lothe J, Ploeg G, Dirkzwager AJE, Clausen T, Tjagvad C, Stavseth MR (2022)
PriSUD-Nordic-Diagnosing and Treating Substance Use Disorders in the Prison Population: Protocol for a Mixed Methods Study
JMIR Res Protoc, 11 (3), e35182
DOI 10.2196/35182, PubMed 35320114

Bækkelund H, Ulvenes P, Boon-Langelaan S, Arnevik EA (2022)
Group treatment for complex dissociative disorders: a randomized clinical trial
BMC Psychiatry, 22 (1), 338
DOI 10.1186/s12888-022-03970-8, PubMed 35578194

Edvardsen HME, Aamodt C, Bogstrand ST, Krajci P, Vindenes V, Rognli EB (2022)
Concentrations of psychoactive substances in blood samples from non-fatal and fatal opioid overdoses
Br J Clin Pharmacol (in press)
DOI 10.1111/bcp.15365, PubMed 35470456

Ericson ØB, Eide D, Lobmaier P, Clausen T (2022)
Staff preferences towards electronic data collection from a national take-home naloxone program: a cross-sectional study
Subst Abuse Treat Prev Policy, 17 (1), 13
DOI 10.1186/s13011-022-00440-y, PubMed 35172848

Kildal E, Hassel B, Bjørnebekk A (2022)
ADHD symptoms and use of anabolic androgenic steroids among male weightlifters
Sci Rep, 12 (1), 9479
DOI 10.1038/s41598-022-12977-w, PubMed 35676515

Melsom HS, Heiestad CM, Eftestøl E, Torp MK, Gundersen K, Bjørnebekk AK, Thorsby PM, Stensløkken KO, Hisdal J (2022)
Reduced arterial elasticity after anabolic-androgenic steroid use in young adult males and mice
Sci Rep, 12 (1), 9707
DOI 10.1038/s41598-022-14065-5, PubMed 35690664

Scarth M, Havnes IA, Jørstad ML, McVeigh J, Van Hout MC, Westlye LT, Torgersen S, Bjørnebekk A (2022)
Severity of anabolic steroid dependence, executive function, and personality traits in substance use disorder patients in Norway
Drug Alcohol Depend, 231, 109275
DOI 10.1016/j.drugalcdep.2022.109275, PubMed 35030506

Publications 2021

Bech AB, Clausen T, Waal H, Delaveris GJM, Skeie I (2021)
Organ pathologies detected post-mortem in patients receiving opioid agonist treatment for opioid use disorder: a nation-wide 2-year cross-sectional study
Addiction, 117 (4), 977-985
DOI 10.1111/add.15705, PubMed 34648218

Bjørnebekk A, Kaufmann T, Hauger LE, Klonteig S, Hullstein IR, Westlye LT (2021)
Long-term Anabolic-Androgenic Steroid Use Is Associated With Deviant Brain Aging
Biol Psychiatry Cogn Neurosci Neuroimaging, 6 (5), 579-589
DOI 10.1016/j.bpsc.2021.01.001, PubMed 33811018

Bukten A, Stavseth MR (2021)
Suicide in prison and after release: a 17-year national cohort study
Eur J Epidemiol, 36 (10), 1075-1083
DOI 10.1007/s10654-021-00782-0, PubMed 34427828

Bækkelund H, Karlsrud I, Hoffart A, Arnevik EA (2021)
Stabilizing group treatment for childhood-abuse related PTSD: a randomized controlled trial
Eur J Psychotraumatol, 12 (1), 1859079
DOI 10.1080/20008198.2020.1859079, PubMed 33537118

Ellingsen MM, Clausen T, Johannesen SL, Martinsen EW, Hallgren M (2021)
Effects of acute exercise on drug craving in adults with poly-substance use disorder. A randomized controlled trial
Ment. Health Phys. Act., 21, 100423
DOI 10.1016/j.mhpa.2021.100423

Finstad J, Røise O, Rosseland LA, Clausen T, Havnes IA (2021)
Discharge from the trauma centre: exposure to opioids, unmet information needs and lack of follow up-a qualitative study among physical trauma survivors
Scand J Trauma Resusc Emerg Med, 29 (1), 121
DOI 10.1186/s13049-021-00938-7, PubMed 34419130

Hauger LE, Havnes IA, Jørstad ML, Bjørnebekk A (2021)
Anabolic androgenic steroids, antisocial personality traits, aggression and violence
Drug Alcohol Depend, 221, 108604
DOI 10.1016/j.drugalcdep.2021.108604, PubMed 33621808

Havnes IA, Muller AE (2021)
Nonprescribed androgen use among women and trans men
Curr Opin Endocrinol Diabetes Obes, 28 (6), 595-603
DOI 10.1097/MED.0000000000000680, PubMed 34709214

Kvarstein EH, Zahl KE, Stänicke LI, Pettersen MS, Baltzersen ÅL, Johansen MS, Eikenaes IU, Arnevik EA, Hummelen B, Wilberg T, Pedersen G (2021)
Vulnerability of personality disorder during the Covid-19 crises - a multicenter survey of treatment experiences among patients referred to treatment
Nord J Psychiatry, 76 (1), 52-63
DOI 10.1080/08039488.2021.1934110, PubMed 34126854

Midgard H, Ulstein K, Backe Ø, Foshaug T, Sørli H, Vennesland K, Nilssen D, Dahl EH, Finbråten AK, Wüsthoff L, Dalgard O (2021)
Hepatitis C treatment and reinfection surveillance among people who inject drugs in a low-threshold program in Oslo, Norway
Int J Drug Policy, 96, 103165
DOI 10.1016/j.drugpo.2021.103165, PubMed 33642182

Rognli EB, Bramness JG, von Soest T (2021)
Smoking in early adulthood is prospectively associated with prescriptions of antipsychotics, mood stabilizers, antidepressants and anxiolytics
Psychol Med, 1-10 (in press)
DOI 10.1017/S0033291720005401, PubMed 33583454

Rognli EB, Aas EM, Drake RE, Marsden J, Anders P, Bond GR, Lystad JU, Reme SE, Arnevik EA (2021)
The effect evaluation of Individual Placement and Support (IPS) for patients with substance use disorders: study protocol for a randomized controlled trial of IPS versus enhanced self-help
Trials, 22 (1), 705
DOI 10.1186/s13063-021-05673-z, PubMed 34654464

Scarth M, Bjørnebekk A (2021)
Androgen abuse and the brain
Curr Opin Endocrinol Diabetes Obes, 28 (6), 604-614
DOI 10.1097/MED.0000000000000675, PubMed 34709215

Stavseth MR (2021)
STATISTICAL DATA ANALYSIS OF 1-2-3
Tidsskr. Nor. Laegeforen., 141 (3), 288

Walderhaug E (2021)
From punishment to help?
Tidsskr Nor Laegeforen, 141 (9)
DOI 10.4045/tidsskr.21.0386, PubMed 34107660

Publications 2020

Bech AB, Clausen T, Waal H, Vindenes V, Edvardsen HE, Frost J, Skeie I (2020)
Post-mortem toxicological analyses of blood samples from 107 patients receiving opioid agonist treatment: substances detected and pooled opioid and benzodiazepine concentrations
Addiction, 116 (4), 845-855
DOI 10.1111/add.15211, PubMed 32738014

Brorson HH, Arnevik EA, Rand-Hendriksen K, Duckert F (2020)
Corrigendum to "Drop-out from addiction treatment: A systematic review of risk factors"
Clin Psychol Rev, 76, 101796
DOI 10.1016/j.cpr.2019.101796, PubMed 32067823

Bukten A, Lund IO, Kinner SA, Rognli EB, Havnes IA, Muller AE, Stavseth MR (2020)
Factors associated with drug use in prison - results from the Norwegian offender mental health and addiction (NorMA) study
Health Justice, 8 (1), 10
DOI 10.1186/s40352-020-00112-8, PubMed 32399643

Ellingsen MM, Johannesen SL, Martinsen EW, Dahl SR, Hallgren M (2020)
Effects of Acute Exercise on Drug Craving, Self-Esteem, Mood, and Affect in Adults with Polysubstance Use Disorder: Protocol for a Multicenter Randomized Controlled Trial
JMIR Res Protoc, 9 (10), e18553
DOI 10.2196/18553, PubMed 33048056

Gatti F, Walderhaug E, Kern-Godal A, Lysell J, Arnevik EA (2020)
Complementary horse-assisted therapy for substance use disorders: a randomized controlled trial
Addict Sci Clin Pract, 15 (1), 7
DOI 10.1186/s13722-020-0183-z, PubMed 32019584

Hauger LE, Westlye LT, Bjørnebekk A (2020)
Anabolic androgenic steroid dependence is associated with executive dysfunction
Drug Alcohol Depend, 208, 107874
DOI 10.1016/j.drugalcdep.2020.107874, PubMed 31972519

Havnes IA (2020)
DOPING Addiction, vanity and performance
Tidsskr. Nor. Laegeforen., 140 (5), 496

Havnes IA, Bukten A, Rognli EB, Muller AE (2020)
Use of anabolic-androgenic steroids and other substances prior to and during imprisonment - Results from the Norwegian Offender Mental Health and Addiction (NorMA) study
Drug Alcohol Depend, 217, 108255
DOI 10.1016/j.drugalcdep.2020.108255, PubMed 32949884

Havnes IA, Jørstad ML, Innerdal I, Bjørnebekk A (2020)
Anabolic-androgenic steroid use among women - A qualitative study on experiences of masculinizing, gonadal and sexual effects
Int J Drug Policy, 95, 102876
DOI 10.1016/j.drugpo.2020.102876, PubMed 32736958

Havnes IA, Jørstad ML, McVeigh J, Van Hout MC, Bjørnebekk A (2020)
The Anabolic Androgenic Steroid Treatment Gap: A National Study of Substance Use Disorder Treatment
Subst Abuse, 14, 1178221820904150
DOI 10.1177/1178221820904150, PubMed 32127749

Medved D, Clausen T, Bukten A, Bjørnestad R, Muller AE (2020)
Large and non-specific somatic disease burdens among ageing, long-term opioid maintenance treatment patients
Subst Abuse Treat Prev Policy, 15 (1), 87
DOI 10.1186/s13011-020-00311-4, PubMed 33198799

Mutsaerts HJMM, Petr J, Groot P, Vandemaele P, Ingala S, Robertson AD, Václavů L, Groote I, Kuijf H, Zelaya F, O'Daly O, Hilal S, Wink AM, Kant I, Caan MWA, Morgan C, de Bresser J, Lysvik E, Schrantee A, Bjørnebekk A, Clement P, Shirzadi Z, Kuijer JPA, Wottschel V, Anazodo UC et al. (2020)
ExploreASL: An image processing pipeline for multi-center ASL perfusion MRI studies
Neuroimage, 219, 117031
DOI 10.1016/j.neuroimage.2020.117031, PubMed 32526385

Pape H, Rossow I, Bukten A (2020)
Alcohol Problems among Prisoners: Subgroup Variations, Concurrent Drug Problems, and Treatment Needs
Eur Addict Res, 27 (3), 179-188
DOI 10.1159/000511253, PubMed 33321498

Paap MCS, Hummelen B, Braeken J, Arnevik EA, Walderhaug E, Wilberg T, Berghuis H, Hutsebaut J, Pedersen G (2020)
A multi-center psychometric evaluation of the Severity Indices of Personality Problems 118 (SIPP-118): Do we really need all those facets?
Qual Life Res, 30 (2), 567-575
DOI 10.1007/s11136-020-02654-8, PubMed 33029679

Rand K, Arnevik EA, Walderhaug E (2020)
Quality of life among patients seeking treatment for substance use disorder, as measured with the EQ-5D-3L
J Patient Rep Outcomes, 4 (1), 92
DOI 10.1186/s41687-020-00247-0, PubMed 33165764

Solli KK, Opheim A, Latif ZE, Krajci P, Benth JŠ, Kunoe N, Tanum L (2020)
Adapting treatment length to opioid-dependent individuals' needs and preferences: A 2-year follow-up to a 1-year study of extended-release naltrexone
Addiction, 116 (8), 2084-2093
DOI 10.1111/add.15378, PubMed 33338285

Stavseth MR (2020)
Sensitivity analysis - how robust is the result?
Tidsskr. Nor. Laegeforen., 140 (8), 807

Tonga JB, Eilertsen DE, Solem IKL, Arnevik EA, Korsnes MS, Ulstein ID (2020)
Effect of Self-Efficacy on Quality of Life in People With Mild Cognitive Impairment and Mild Dementia: The Mediating Roles of Depression and Anxiety
Am J Alzheimers Dis Other Demen, 35, 1533317519885264
DOI 10.1177/1533317519885264, PubMed 31916847

Tonga JB, Šaltytė Benth J, Arnevik EA, Werheid K, Korsnes MS, Ulstein ID (2020)
Managing depressive symptoms in people with mild cognitive impairment and mild dementia with a multicomponent psychotherapy intervention: a randomized controlled trial
Int Psychogeriatr, 33 (3), 217-231
DOI 10.1017/S1041610220000216, PubMed 32131911

Vaskinn A, Hauger LE, Bjørnebekk A (2020)
Theory of mind in users of anabolic androgenic steroids
Psychopharmacology (Berl), 237 (10), 3191-3199
DOI 10.1007/s00213-020-05603-y, PubMed 32623552

Welle-Strand GK, Skurtveit S, Abel KF, Chalabianloo F, Sarfi M (2020)
Living a normal life? Follow-up study of women who had been in opioid maintenance treatment during pregnancy
J Subst Abuse Treat, 113, 108004
DOI 10.1016/j.jsat.2020.108004, PubMed 32359675

Waal H, Vold JH, Skurtveit SO (2020)
Quetiapine abuse - myth or reality?
Tidsskr. Nor. Laegeforen., 140 (12), 1228-1230

Publications 2019

Arnevik EA, Pedersen G, Walderhaug E, Lien I, Wilberg T, Hummelen B (2019)
Measuring Personality Problems in Patients With Substance Use Disorders: A Cross-Sample Validation
J Dual Diagn, 15 (4), 324-332
DOI 10.1080/15504263.2019.1668583, PubMed 31571533

Bech AB, Clausen T, Waal H, Šaltytė Benth J, Skeie I (2019)
Mortality and causes of death among patients with opioid use disorder receiving opioid agonist treatment: a national register study
BMC Health Serv Res, 19 (1), 440
DOI 10.1186/s12913-019-4282-z, PubMed 31266495

Brorson HH, Arnevik EA, Rand K (2019)
Predicting Dropout from Inpatient Substance Use Disorder Treatment: A Prospective Validation Study of the OQ-Analyst
Subst Abuse, 13, 1178221819866181
DOI 10.1177/1178221819866181, PubMed 31452601

Hauger LE, Sagoe D, Vaskinn A, Arnevik EA, Leknes S, Jørstad ML, Bjørnebekk A (2019)
Anabolic androgenic steroid dependence is associated with impaired emotion recognition
Psychopharmacology (Berl), 236 (9), 2667-2676
DOI 10.1007/s00213-019-05239-7, PubMed 30941469

Hauger LE, Westlye LT, Fjell AM, Walhovd KB, Bjørnebekk A (2019)
Structural brain characteristics of anabolic-androgenic steroid dependence in men
Addiction, 114 (8), 1405-1415
DOI 10.1111/add.14629, PubMed 30955206

Havnes IA, Jørstad ML, Wisløff C (2019)
Anabolic-androgenic steroid users receiving health-related information; health problems, motivations to quit and treatment desires
Subst Abuse Treat Prev Policy, 14 (1), 20
DOI 10.1186/s13011-019-0206-5, PubMed 31096999

Helverschou SB, Brunvold AR, Arnevik EA (2019)
Treating Patients With Co-occurring Autism Spectrum Disorder and Substance Use Disorder: A Clinical Explorative Study
Subst Abuse, 13, 1178221819843291
DOI 10.1177/1178221819843291, PubMed 31024216

Latif ZE, Šaltyte Benth J, Solli KK, Opheim A, Kunoe N, Krajci P, Sharma-Haase K, Tanum L (2019)
Anxiety, Depression, and Insomnia Among Adults With Opioid Dependence Treated With Extended-Release Naltrexone vs Buprenorphine-Naloxone: A Randomized Clinical Trial and Follow-up Study
JAMA Psychiatry, 76 (2), 127-134
DOI 10.1001/jamapsychiatry.2018.3537, PubMed 30566177

Latif ZE, Solli KK, Opheim A, Kunoe N, Benth JŠ, Krajci P, Sharma-Haase K, Tanum L (2019)
No increased pain among opioid-dependent individuals treated with extended-release naltrexone or buprenorphine-naloxone: A 3-month randomized study and 9-month open-treatment follow-up study
Am J Addict, 28 (2), 77-85
DOI 10.1111/ajad.12859, PubMed 30701613

Morland J, Waal H (2019)
"The entire common catalog" in the treatment of drug disorders
Tidsskr. Nor. Laegeforen., 139 (3), 240-242

Muller AE, Bukten A (2019)
Measuring the quality of life of incarcerated individuals
Int J Prison Health, 15 (1), 1-13
DOI 10.1108/IJPH-02-2018-0005, PubMed 30827162

Pedersen G, Arnevik EA, Hummelen B, Walderhaug E, Wilberg T (2019)
Psychometric Properties of the Severity Indices of Personality Problems (SIPP) in Two Samples A Norwegian Community Sample and Clinical Samples of Patients With and Without Personality Disorders
Eur. J. Psychol. Assess., 35 (5), 698-711
DOI 10.1027/1015-5759/a000436

Pettersen H, Brodahl M, Rundgren J, Davidson L, Havnes IA (2019)
Partnering with persons in long-term recovery from substance use disorder: experiences from a collaborative research project
Harm Reduct J, 16 (1), 40
DOI 10.1186/s12954-019-0310-x, PubMed 31234878

Rognli EB, Bramness JG, von Soest T (2019)
Cannabis use in early adulthood is prospectively associated with prescriptions of antipsychotics, mood stabilizers, and antidepressants
Acta Psychiatr Scand, 141 (2), 149-156
DOI 10.1111/acps.13104, PubMed 31560790

Solli KK, Kunoe N, Latif ZE, Sharma-Haase K, Opheim A, Krajci P, Gaulen Z, Šaltytė Benth J, Tanum L (2019)
Availability of Extended-Release Naltrexone May Increase the Number of Opioid-Dependent Individuals in Treatment: Extension of a Randomized Clinical Trial
Eur Addict Res, 25 (6), 303-309
DOI 10.1159/000501931, PubMed 31340204

Sømhovd M, Hagen E, Bergly T, Arnevik EA (2019)
The Montreal Cognitive Assessment as a predictor of dropout from residential substance use disorder treatment
Heliyon, 5 (3), e01282
DOI 10.1016/j.heliyon.2019.e01282, PubMed 31025003

Walderhaug E, Seim-Wikse KJ, Enger A, Milin O (2019)
Polydrug use - prevalence and registration
Tidsskr Nor Laegeforen, 139 (13)
DOI 10.4045/tidsskr.19.0251, PubMed 31556532

Walderhaug E, Seim-Wikse KJ, Enger A, Milin O (2019)
Polydrug Use - prevalence and registration
Tidsskr. Nor. Laegeforen., 139 (13), 1279-1281

Publications 2018

Andersson HW, Steinsbekk A, Walderhaug E, Otterholt E, Nordfjærn T (2018)
Predictors of Dropout From Inpatient Substance Use Treatment: A Prospective Cohort Study
Subst Abuse, 12, 1178221818760551
DOI 10.1177/1178221818760551, PubMed 29531472

Bækkelund H, Frewen P, Lanius R, Ottesen Berg A, Arnevik EA (2018)
Trauma-related altered states of consciousness in post-traumatic stress disorder patients with or without comorbid dissociative disorders
Eur J Psychotraumatol, 9 (1), 1544025
DOI 10.1080/20008198.2018.1544025, PubMed 30455853

Ellingsen MM, Johannesen SL, Martinsen EW, Hallgren M (2018)
Effects of acute exercise on drug craving, self-esteem, mood and affect in adults with poly-substance dependence: Feasibility and preliminary findings
Drug Alcohol Rev, 37 (6), 789-793
DOI 10.1111/dar.12818, PubMed 29869351

Fosen JT, Høiseth G, Sempio C, Giarratana N, Enger A, Mørland J, Morini L (2018)
Hair EtG: Alterations in segment levels accompanying hair growth
Drug Test Anal, 11 (1), 112-118
DOI 10.1002/dta.2474, PubMed 30084156

Hagen E, Sømhovd M, Hesse M, Arnevik EA, Erga AH (2018)
Measuring cognitive impairment in young adults with polysubstance use disorder with MoCA or BRIEF-A - The significance of psychiatric symptoms
J Subst Abuse Treat, 97, 21-27
DOI 10.1016/j.jsat.2018.11.010, PubMed 30577896

Henriksen K, Jacobsen JA, Henriksen EM, Gomes L, Waal H, Krajci P (2018)
The LASSO Program in Oslo: Harm Reduction Using Buprenorphine-Naloxone (Suboxone®) in a Low Threshold Setting
Eur Addict Res, 24 (6), 286-292
DOI 10.1159/000495188, PubMed 30466108

Haabrekke K, Siqveland T, Nygaaard E, Bjornebekk A, Slinning K, Wentzel-Larsen T, Walhovd KB, Smith L, Moe V (2018)
COGNITIVE AND SOCIOEMOTIONAL FUNCTIONING AT 4½ YEARS IN CHILDREN BORN TO MOTHERS WHO HAVE RECEIVED TREATMENT FOR SUBSTANCE-ABUSE PROBLEMS WHILE PREGNANT
Infant Ment Health J, 39 (5), 581-594
DOI 10.1002/imhj.21733, PubMed 30084491

Jørstad ML, Skogheim TS, Bergsund HB (2018)
“Mer hjelp, mindre moralpreken”: Hva brukere av anabole-androgene steroider ønsker fra helsetjenestene
Nordisk Alkohol Nark, 35 (1), 69-76
DOI 10.1177/1455072517748871, PubMed 32934514

Madah-Amiri D, Skulberg AK, Braarud AC, Dale O, Heyerdahl F, Lobmaier P, Clausen T (2018)
Ambulance-attended opioid overdoses: An examination into overdose locations and the role of a safe injection facility
Subst Abus, 40 (3), 383-388
DOI 10.1080/08897077.2018.1485130, PubMed 29949448

Muller AE, Havnes IA, Rognli EB, Bukten A (2018)
Inmates with Harmful Substance Use Increase Both Exercise and Nicotine Use Under Incarceration
Int J Environ Res Public Health, 15 (12)
DOI 10.3390/ijerph15122663, PubMed 30486386

Ringen PA, Faerden A, Antonsen B, Falk RS, Mamen A, Rognli EB, Solberg DK, Andreassen OA, Martinsen EW (2018)
Cardiometabolic risk factors, physical activity and psychiatric status in patients in long-term psychiatric inpatient departments
Nord J Psychiatry, 72 (4), 296-302
DOI 10.1080/08039488.2018.1449012, PubMed 29523041

Ringen PA, Falk RS, Antonsen B, Faerden A, Mamen A, Rognli EB, Solberg DK, Martinsen EW, Andreassen OA (2018)
Using motivational techniques to reduce cardiometabolic risk factors in long term psychiatric inpatients: a naturalistic interventional study
BMC Psychiatry, 18 (1), 255
DOI 10.1186/s12888-018-1832-6, PubMed 30111298

Solli KK, Latif ZE, Opheim A, Krajci P, Sharma-Haase K, Benth JŠ, Tanum L, Kunoe N (2018)
Effectiveness, safety and feasibility of extended-release naltrexone for opioid dependence: a 9-month follow-up to a 3-month randomized trial
Addiction, 113 (10), 1840-1849
DOI 10.1111/add.14278, PubMed 29806872

Publications 2017

Bukten A, Stavseth MR, Skurtveit S, Tverdal A, Strang J, Clausen T (2017)
High risk of overdose death following release from prison: variations in mortality during a 15-year observation period
Addiction, 112 (8), 1432-1439
DOI 10.1111/add.13803, PubMed 28319291

Fosen JT, Morini L, Sempio C, Giarratana N, Enger A, Mørland J, Høiseth G (2017)
Ethyl Glucuronide Elimination Kinetics in Fingernails and Comparison to Levels in Hair
Alcohol Alcohol, 52 (5), 580-586
DOI 10.1093/alcalc/agx035, PubMed 28591773

Hagen E, Erga AH, Hagen KP, Nesvåg SM, McKay JR, Lundervold AJ, Walderhaug E (2017)
One-year sobriety improves satisfaction with life, executive functions and psychological distress among patients with polysubstance use disorder
J Subst Abuse Treat, 76, 81-87
DOI 10.1016/j.jsat.2017.01.016, PubMed 28159440

Hagen E, Erga AH, Nesvåg SM, McKay JR, Lundervold AJ, Walderhaug E (2017)
One-year abstinence improves ADHD symptoms among patients with polysubstance use disorder
Addict Behav Rep, 6, 96-101
DOI 10.1016/j.abrep.2017.08.005, PubMed 29450242

Kjoesnes R, Waal H, Hauff E, Gossop M (2017)
Severe trauma among substance users in opioid maintenance treatment: users' assessment of worst trauma and clinical assessment of PTSD
Heroin Addict. Relat. Clin. Probl., 19 (1), 5-11

Madah-Amiri D, Clausen T, Lobmaier P (2017)
Rapid widespread distribution of intranasal naloxone for overdose prevention
Drug Alcohol Depend, 173, 17-23
DOI 10.1016/j.drugalcdep.2016.12.013, PubMed 28182982

Nyhagen HT, Waal H (2017)
Den aldrende LAR pasienten
Nordisk Alkohol Nark, 34 (1), 72-79
DOI 10.1177/1455072516682637, PubMed 32934468

Tanum L, Solli KK, Latif ZE, Benth JŠ, Opheim A, Sharma-Haase K, Krajci P, Kunøe N (2017)
Effectiveness of Injectable Extended-Release Naltrexone vs Daily Buprenorphine-Naloxone for Opioid Dependence: A Randomized Clinical Noninferiority Trial
JAMA Psychiatry, 74 (12), 1197-1205
DOI 10.1001/jamapsychiatry.2017.3206, PubMed 29049469

Wright N, Reimer J, Somaini L, Roncero C, Maremmani I, Simon N, Krajci P, Littlewood R, D'Agnone O, Alho H, Rolland B (2017)
Are we ready to treat hepatitis C virus in individuals with opioid use disorder: assessment of readiness in European countries on the basis of an expert-generated model
Eur J Gastroenterol Hepatol, 29 (11), 1206-1214
DOI 10.1097/MEG.0000000000000962, PubMed 28914697

Publications 2016

Arnevik EA, Helverschou SB (2016)
Autism Spectrum Disorder and Co-occurring Substance Use Disorder - A Systematic Review
Subst Abuse, 10, 69-75
DOI 10.4137/SART.S39921, PubMed 27559296

Bramness JG, Rognli EB (2016)
Psychosis induced by amphetamines
Curr Opin Psychiatry, 29 (4), 236-41
DOI 10.1097/YCO.0000000000000254, PubMed 27175554

Hagen E, Erga AH, Hagen KP, Nesvåg SM, McKay JR, Lundervold AJ, Walderhaug E (2016)
Assessment of Executive Function in Patients With Substance Use Disorder: A Comparison of Inventory- and Performance-Based Assessment
J Subst Abuse Treat, 66, 1-8
DOI 10.1016/j.jsat.2016.02.010, PubMed 27211990

Henriksen K, Waal H, Krajci P (2016)
Will non-compliant 'hard-to-treat' opioid-dependent patients profit from low threshold methadone treatment? A prospective 15-month evaluation of patients on Low Dosage Methadone treatment at Oslo University Hospital
Heroin Addict. Relat. Clin. Probl., 18 (3), 23-27

Kern-Godal A, Brenna IH, Arnevik EA, Ravndal E (2016)
More Than Just a Break from Treatment: How Substance Use Disorder Patients Experience the Stable Environment in Horse-Assisted Therapy
Subst Abuse, 10, 99-108
DOI 10.4137/SART.S40475, PubMed 27746677

Kern-Godal A, Brenna IH, Kogstad N, Arnevik EA, Ravndal E (2016)
Contribution of the patient-horse relationship to substance use disorder treatment: Patients' experiences
Int J Qual Stud Health Well-being, 11, 31636
DOI 10.3402/qhw.v11.31636, PubMed 27291162

Lien IA, Arnevik EA (2016)
Assessment of personality problems among patients with substance use disorders
Nord. Stud. Alcohol Drugs, 33 (4), 399-414
DOI 10.1515/nsad-2016-0033

Madah-Amiri D, Clausen T, Lobmaier P (2016)
Utilizing a train-the-trainer model for multi-site naloxone distribution programs
Drug Alcohol Depend, 163, 153-6
DOI 10.1016/j.drugalcdep.2016.04.007, PubMed 27107847

Madah-Amiri D, Clausen T, Myrmel L, Brattebø G, Lobmaier P (2016)
Circumstances surrounding non-fatal opioid overdoses attended by ambulance services
Drug Alcohol Rev, 36 (3), 288-294
DOI 10.1111/dar.12451, PubMed 28036135

Maremmani I, Rolland B, Somaini L, Roncero C, Reimer J, Wright N, Littlewood R, Krajci P, Alho H, D'Agnone O, Simon N (2016)
Buprenorphine dosing choices in specific populations: review of expert opinion
Expert Opin Pharmacother, 17 (13), 1727-31
DOI 10.1080/14656566.2016.1209486, PubMed 27376622

Nordheim K, Walderhaug E, Alstadius S, Kern-Godal A, Arnevik E, Duckert F (2016)
Young adults' reasons for dropout from residential substance use disorder treatment
Qual Soc Work, 17 (1), 24-40
DOI 10.1177/1473325016654559, PubMed 29276430

Rognli EB, Bramness JG, Skurtveit S, Bukten A (2016)
Substance use and sociodemographic background as risk factors for lifetime psychotic experiences in a non-clinical sample
J Subst Abuse Treat, 74, 42-47
DOI 10.1016/j.jsat.2016.12.007, PubMed 28132699

Westlye LT, Kaufmann T, Alnæs D, Hullstein IR, Bjørnebekk A (2016)
Brain connectivity aberrations in anabolic-androgenic steroid users
Neuroimage Clin, 13, 62-69
DOI 10.1016/j.nicl.2016.11.014, PubMed 27942448

Publications 2015

Alho H, D'Agnone O, Krajci P, McKeganey N, Maremmani I, Reimer J, Roncero C, Somaini L, Wright N, Littlewood R (2015)
The extent of misuse and diversion of medication for agonist opioid treatment: A review and expert opinions
Heroin Addict. Relat. Clin. Probl., 17 (2-3), 25-33

Alho H, Jansen J, Krajci P, Littlewood R, Runarsdottir V, Nyberg F (2015)
Misuse and diversion of agonist opioid treatment medicines: assessment of the scale of the problem and review of the changing environment for care in the Nordic countries
Heroin Addict. Relat. Clin. Probl., 17 (5), 43-49

Bernard JP, Khiabani HZ, Hilberg T, Karinen R, Slørdal L, Waal H, Mørland J (2015)
Characteristics of methadone-related fatalities in Norway
J Forensic Leg Med, 36, 114-20
DOI 10.1016/j.jflm.2015.09.011, PubMed 26439870

Bukten A, Lund IO, Rognli EB, Stavseth MR, Lobmaier P, Skurtveit S, Clausen T, Kunøe N (2015)
The Norwegian Offender Mental Health and Addiction Study - Design and Implementation of a National Survey and Prospective Cohort Study
Subst Abuse, 9 (Suppl 2), 59-66
DOI 10.4137/SaRt.S23546, PubMed 26648732

Gaasland A, Havnes IA, Venberget M, Andresen JF (2015)
[Re: All suicides are not due to treatment failure]
Tidsskr Nor Laegeforen, 135 (18), 1625
DOI 10.4045/tidsskr.15.0964, PubMed 26442723

Kern-Godal A, Arnevik EA, Walderhaug E, Ravndal E (2015)
Substance use disorder treatment retention and completion: a prospective study of horse-assisted therapy (HAT) for young adults
Addict Sci Clin Pract, 10, 21
DOI 10.1186/s13722-015-0043-4, PubMed 26466788

Medhus S, Rognli EB, Gossop M, Holm B, Mørland J, Bramness JG (2015)
Amphetamine-induced psychosis: Transition to schizophrenia and mortality in a small prospective sample
Am J Addict, 24 (7), 586-9
DOI 10.1111/ajad.12274, PubMed 26332037

Nordal K, Øiestad EL, Enger A, Christophersen AS, Vindenes V (2015)
Detection Times of Diazepam, Clonazepam, and Alprazolam in Oral Fluid Collected From Patients Admitted to Detoxification, After High and Repeated Drug Intake
Ther Drug Monit, 37 (4), 451-60
DOI 10.1097/FTD.0000000000000174, PubMed 25549207

Opdal MS, Arnesen M, Müller LD, Hullstein I, Sayed K, Brørs O, Kringen M, Sagedal S, Gjesdal K, Krajci P (2015)
Effects of Hemodialysis on Methadone Pharmacokinetics and QTc
Clin Ther, 37 (7), 1594-9
DOI 10.1016/j.clinthera.2015.04.009, PubMed 25963997

Reimer J, Wright N, Somaini L, Roncero C, Maremmani I, McKeganey N, Littlewood R, Krajci P, Alho H, D'Agnone O (2015)
The Impact of Misuse and Diversion of Opioid Substitution Treatment Medicines: Evidence Review and Expert Consensus
Eur Addict Res, 22 (2), 99-106
DOI 10.1159/000438988, PubMed 26426530

Rognli EB, Berge J, Håkansson A, Bramness JG (2015)
Long-term risk factors for substance-induced and primary psychosis after release from prison. A longitudinal study of substance users
Schizophr Res, 168 (1-2), 185-90
DOI 10.1016/j.schres.2015.08.032, PubMed 26359848

Wright N, D'Agnone O, Krajci P, Littlewood R, Alho H, Reimer J, Roncero C, Somaini L, Maremmani I (2015)
Addressing misuse and diversion of opioid substitution medication: guidance based on systematic evidence review and real-world experience
J Public Health (Oxf), 38 (3), e368-e374
DOI 10.1093/pubmed/fdv150, PubMed 26508767

Publications 2014

Abel KF, Bramness JG, Martinsen EW (2014)
Stimulant medication for ADHD in opioid maintenance treatment
J Dual Diagn, 10 (1), 32-8
DOI 10.1080/15504263.2013.867657, PubMed 25392060

Andås HT, Krabseth HM, Enger A, Marcussen BN, Haneborg AM, Christophersen AS, Vindenes V, Øiestad EL (2014)
Detection time for THC in oral fluid after frequent cannabis smoking
Ther Drug Monit, 36 (6), 808-14
DOI 10.1097/FTD.0000000000000092, PubMed 24819969

Havnes IA, Clausen T, Brux C, Middelthon AL (2014)
The role of substance use and morality in violent crime - a qualitative study among imprisoned individuals in opioid maintenance treatment
Harm Reduct J, 11, 24
DOI 10.1186/1477-7517-11-24, PubMed 25142321

Havnes IA, Clausen T, Middelthon AL (2014)
Execution of control among 'non-compliant', imprisoned individuals in opioid maintenance treatment
Int J Drug Policy, 25 (3), 480-5
DOI 10.1016/j.drugpo.2014.01.018, PubMed 24594221

Kunøe N, Lobmaier P, Ngo H, Hulse G (2014)
Injectable and implantable sustained release naltrexone in the treatment of opioid addiction
Br J Clin Pharmacol, 77 (2), 264-71
DOI 10.1111/bcp.12011, PubMed 23088328

Pettersen H, Ruud T, Ravndal E, Havnes I, Landheim A (2014)
Engagement in assertive community treatment as experienced by recovering clients with severe mental illness and concurrent substance use
Int J Ment Health Syst, 8 (1), 40
DOI 10.1186/1752-4458-8-40, PubMed 25389446

Waal H (2014)
[Advances in the detention cell]
Tidsskr Nor Laegeforen, 134 (3), 263
DOI 10.4045/tidsskr.14.0015, PubMed 24518445

Publications 2013

Amble I, Gude T, Stubdal S, Oktedalen T, Skjorten AM, Andersen BJ, Solbakken OA, Brorson HH, Arnevik E, Lambert MJ, Wampold BE (2013)
Psychometric properties of the outcome questionnaire-45.2: the Norwegian version in an international context
Psychother Res, 24 (4), 504-13
DOI 10.1080/10503307.2013.849016, PubMed 24188797

Havnes IA, Clausen T, Middelthon AL (2013)
'Diversion' of methadone or buprenorphine: 'harm' versus 'helping'
Harm Reduct J, 10, 24
DOI 10.1186/1477-7517-10-24, PubMed 24131626

Helseth V, Samet S, Johnsen J, Bramness JG, Waal H (2013)
Independent or Substance-Induced Mental Disorders? An Investigation of Comorbidity in an Acute Psychiatric Unit
J. Dual Diagn., 9 (1), 78-86
DOI 10.1080/15504263.2012.749142

Publications 2012

Bernard JP, Havnes I, Slørdal L, Waal H, Mørland J, Khiabani HZ (2012)
Methadone-related deaths in Norway
Forensic Sci Int, 224 (1-3), 111-6
DOI 10.1016/j.forsciint.2012.11.010, PubMed 23246070

Pedersen K, Waal H, Kringlen E (2012)
Patients with nonaffective psychosis are at increased risk for heroin use disorders
Eur Addict Res, 18 (3), 124-9
DOI 10.1159/000334613, PubMed 22354141

Skeie I, Brekke M, Clausen T, Gossop M, Lindbaek M, Reinertsen E, Thoresen M, Waal H (2012)
Increased somatic morbidity in the first year after leaving opioid maintenance treatment: results from a Norwegian cohort study
Eur Addict Res, 19 (4), 194-201
DOI 10.1159/000345229, PubMed 23257574

Waal H, Brekke M, Clausen T, Lindbæk M, Rosta J, Skeie I, Aasland OG (2012)
General practitioners' views on drug-assisted rehabilitation
Tidsskr Nor Laegeforen, 132 (16), 1861-6
DOI 10.4045/tidsskr.12.0124, PubMed 22986970

Publications 2011

Bukten A, Skurtveit S, Gossop M, Waal H, Stangeland P, Havnes I, Clausen T (2011)
Engagement with opioid maintenance treatment and reductions in crime: a longitudinal national cohort study
Addiction, 107 (2), 393-9
DOI 10.1111/j.1360-0443.2011.03637.x, PubMed 21883606

Bukten A, Skurtveit S, Stangeland P, Gossop M, Willersrud AB, Waal H, Havnes I, Clausen T (2011)
Criminal convictions among dependent heroin users during a 3-year period prior to opioid maintenance treatment: a longitudinal national cohort study
J Subst Abuse Treat, 41 (4), 407-14
DOI 10.1016/j.jsat.2011.06.006, PubMed 21839605

Lobmaier PP, Kunøe N, Gossop M, Waal H (2011)
Naltrexone depot formulations for opioid and alcohol dependence: a systematic review
CNS Neurosci Ther, 17 (6), 629-36
DOI 10.1111/j.1755-5949.2010.00194.x, PubMed 21554565

Skeie I, Brekke M, Gossop M, Lindbaek M, Reinertsen E, Thoresen M, Waal H (2011)
Changes in somatic disease incidents during opioid maintenance treatment: results from a Norwegian cohort study
BMJ Open, 1 (1), e000130
DOI 10.1136/bmjopen-2011-000130, PubMed 22021771

Vindenes V, Yttredal B, Oiestad EL, Waal H, Bernard JP, Mørland JG, Christophersen AS (2011)
Oral fluid is a viable alternative for monitoring drug abuse: detection of drugs in oral fluid by liquid chromatography-tandem mass spectrometry and comparison to the results from urine samples from patients treated with Methadone or Buprenorphine
J Anal Toxicol, 35 (1), 32-9
DOI 10.1093/anatox/35.1.32, PubMed 21219701

Publications 2010

Bramness JG, Clausen T, Duckert F, Ravndal E, Waal H (2010)
Addiction research centres and the nurturing of creativity The Norwegian Centre for Addiction Research (SERAF)
Addiction, 106 (8), 1381-5
DOI 10.1111/j.1360-0443.2010.03086.x, PubMed 20735364

Brekke M, Vetlesen A, Høiby L, Skeie I (2010)
[Quality of life among patients in drug-assisted rehabilitation programmes]
Tidsskr Nor Laegeforen, 130 (13), 1340-2
DOI 10.4045/tidsskr.09.1117, PubMed 20596114

Lobmaier P, Gossop M, Waal H, Bramness J (2010)
The pharmacological treatment of opioid addiction--a clinical perspective
Eur J Clin Pharmacol, 66 (6), 537-45
DOI 10.1007/s00228-010-0793-6, PubMed 20169438

Lobmaier PP, Kunøe N, Gossop M, Katevoll T, Waal H (2010)
Naltrexone implants compared to methadone: outcomes six months after prison release
Eur Addict Res, 16 (3), 139-45
DOI 10.1159/000313336, PubMed 20424458

Ravndal E, Amundsen EJ (2010)
Mortality among drug users after discharge from inpatient treatment: an 8-year prospective study
Drug Alcohol Depend, 108 (1-2), 65-9
DOI 10.1016/j.drugalcdep.2009.11.008, PubMed 20022184

Ravndal E, Vaglum P (2010)
The Millon Clinical Multiaxial Inventory II: stability over time? A seven-year follow-up study of substance abusers in treatment
Eur Addict Res, 16 (3), 146-51
DOI 10.1159/000313337, PubMed 20424459

Waal H (2010)
NISUD—progress, backlash or sidetrack?
Addiction, 105 (12), 2050-1; discussion 2056
DOI 10.1111/j.1360-0443.2010.03116.x, PubMed 21105301

Publications 2009

Arnevik E, Wilberg T, Monsen JT, Andrea H, Karterud S (2009)
A cross-national validity study of the Severity Indices of Personality Problems (SIPP-118)
Personal. Ment. Health, 3 (1), 41-55
DOI 10.1002/pmh.60

Clausen T, Havnes IA, Waal H (2009)
[Overdose statistics--a complicated account]
Tidsskr Nor Laegeforen, 129 (21), 2233-6
DOI 10.4045/tidsskr.08.0605, PubMed 19898571

Shaygani S, Waal H (2009)
[Treatment of opioid withdrawal]
Tidsskr Nor Laegeforen, 129 (2), 114-5
DOI 10.4045/tidsskr.09.32466, PubMed 19151804

Publications 2008

Skeie I, Brekke M, Lindbaek M, Waal H (2008)
Somatic health among heroin addicts before and during opioid maintenance treatment: a retrospective cohort study
BMC Public Health, 8, 43
DOI 10.1186/1471-2458-8-43, PubMed 18237421

Publications 2007

Kornør H, Waal H, Sandvik L (2007)
Time-limited buprenorphine replacement therapy for opioid dependence: 2-year follow-up outcomes in relation to programme completion and current agonist therapy status
Drug Alcohol Rev, 26 (2), 135-41
DOI 10.1080/09595230601146603, PubMed 17364848

Kunøe N, Waal H (2007)
Opioid overdose deaths can occur in patients with naltrexone implants
Med J Aust, 187 (1), 56; author reply 56-7
DOI 10.5694/j.1326-5377.2007.tb01124.x, PubMed 17605713

Pedersen K, Sandvik L, Waal H (2007)
Evaluation of DTES - A simple drug-taking scale
Addict. Res. Theory, 15 (6), 637-649
DOI 10.1080/16066350701433209

Skeie I, Brekke M, Lindbaek M, Waal H (2007)
[General practitioners can take responsibility for medication-based rehabilitation]
Tidsskr Nor Laegeforen, 127 (3), 296-7
PubMed 17279108

Waal H, Krook AL, Hansteen V (2007)
[Methadone treatment and heart arrhythmia]
Tidsskr Nor Laegeforen, 127 (4), 459; author reply 459-60
PubMed 17304281

Waal H, Krook AL, Hansteen V (2007)
[Methadone and arrhythmia--final comment]
Tidsskr Nor Laegeforen, 127 (7), 913; author reply 913
PubMed 17435820

Publications 2006

Kornør H, Waal H, Ali RL (2006)
Abstinence-orientated buprenorphine replacement therapy for young adults in out-patient counselling
Drug Alcohol Rev, 25 (2), 123-30
DOI 10.1080/09595230500537209, PubMed 16627301

Publications 2005

Kornør H, Waal H (2005)
From opioid maintenance to abstinence: a literature review
Drug Alcohol Rev, 24 (3), 267-74
DOI 10.1080/09595230500170241, PubMed 16096130

Kunøe N, Lobmaier P (2005)
Blame the counselling, not the implant. A response to Oliver, Horspool & Keen (2005)
Addiction, 100 (7), 1027-8; author reply 1028-9
DOI 10.1111/j.1360-0443.2005.01209.x, PubMed 15955020

Vermund H, Krajci P, Eide TJ, Winther F (2005)
Histopathological grading of laryngectomy specimens
APMIS, 113 (7-8), 473-88
DOI 10.1111/j.1600-0463.2005.apm_24.x, PubMed 16086817

Publications 2004

Kornør H, Waal H (2004)
[Methadone dose, treatment duration and heroin use in drug-assisted rehabilitation]
Tidsskr Nor Laegeforen, 124 (3), 332-4
PubMed 14963504

Krook AL, Waal H, Hansteen V (2004)
[Routine ECG in methadone-assisted rehabilitation is wrong prioritization]
Tidsskr Nor Laegeforen, 124 (22), 2940-1
PubMed 15550974

Olsen L, Christophersen AS, Frogopsahl G, Waal H, Mørland J (2004)
Plasma concentrations during naltrexone implant treatment of opiate-dependent patients
Br J Clin Pharmacol, 58 (2), 219-22
DOI 10.1111/j.1365-2125.2004.02122.x, PubMed 15255807

Vermund H, Krajci P, Eide TJ, Winther F (2004)
Laryngectomy whole organ serial sections--histological parameters correlated with recurrence rate
Acta Oncol, 43 (1), 98-107
DOI 10.1080/02841860310020366, PubMed 15068327

Waal H, Kornor H (2004)
Abstinence-oriented therapies for opiate addicts
Curr. Opin. Psychiatr., 17 (3), 169-174
DOI 10.1097/00001504-200405000-00004

Publications 2003

Bachs L, Waal H (2003)
[Naltrexone in the treatment of addiction]
Tidsskr Nor Laegeforen, 123 (12), 1665-7
PubMed 12821984

Waal H (2003)
[Tragedies in drunk cells]
Tidsskr Nor Laegeforen, 123 (8), 1047
PubMed 12760215

Publications 2002

Bramness JG, Bachs LC, Waal H (2002)
[Buprenorphine as maintenance treatment in rehabilitation of heroin addicts]
Tidsskr Nor Laegeforen, 122 (25), 2452-4
PubMed 12448114

Krook AL, Brørs O, Dahlberg J, Grouff K, Magnus P, Røysamb E, Waal H (2002)
A placebo-controlled study of high dose buprenorphine in opiate dependents waiting for medication-assisted rehabilitation in Oslo, Norway
Addiction, 97 (5), 533-42
DOI 10.1046/j.1360-0443.2002.00090.x, PubMed 12033654

Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, Gascoyne RD, Muller-Hermelink HK, Smeland EB, Giltnane JM, Hurt EM, Zhao H, Averett L, Yang L, Wilson WH, Jaffe ES, Simon R, Klausner RD, Powell J, Duffey PL, Longo DL, Greiner TC, Weisenburger DD, Sanger WG, Dave BJ et al. (2002)
The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma
N Engl J Med, 346 (25), 1937-47
DOI 10.1056/NEJMoa012914, PubMed 12075054

Publications 2000

Walby FA, Borg P, Eikeseth PH, Neegaard E, Kjerpeseth K, Bruvik S, Waal H (2000)
[Use of methadone in the treatment of psychotic patients with heroin dependence]
Tidsskr Nor Laegeforen, 120 (2), 195-8
PubMed 10851915

Wiatrowska B, Krajci P, Berner A (2000)
[Pseudo-Meigs' syndrome]
Tidsskr Nor Laegeforen, 120 (3), 364-6
PubMed 10827530

Publications 1999

Blix O, Bruvik S, Waal H (1999)
[The Oslo methadone project]
Tidsskr Nor Laegeforen, 119 (2), 242-6
PubMed 10081358

Johansen FE, Pekna M, Norderhaug IN, Haneberg B, Hietala MA, Krajci P, Betsholtz C, Brandtzaeg P (1999)
Absence of epithelial immunoglobulin A transport, with increased mucosal leakiness, in polymeric immunoglobulin receptor/secretory component-deficient mice
J Exp Med, 190 (7), 915-22
DOI 10.1084/jem.190.7.915, PubMed 10510081

Nilsen EM, Johansen FE, Kvale D, Krajci P, Brandtzaeg P (1999)
Different regulatory pathways employed in cytokine-enhanced expression of secretory component and epithelial HLA class I genes
Eur J Immunol, 29 (1), 168-79
DOI 10.1002/(SICI)1521-4141(199901)29:01<168::AID-IMMU168>3.0.CO;2-8, PubMed 9933098

Norderhaug IN, Johansen FE, Krajci P, Brandtzaeg P (1999)
Domain deletions in the human polymeric Ig receptor disclose differences between its dimeric IgA and pentameric IgM interaction
Eur J Immunol, 29 (10), 3401-9
DOI 10.1002/(SICI)1521-4141(199910)29:10<3401::AID-IMMU3401>3.0.CO;2-G, PubMed 10540352

Waal H, Morland J (1999)
Addiction as impeded rationality
ADDICTION: ENTRIES AND EXITS, 120-147

Publications 1998

Johansen FE, Bosløven BA, Krajci P, Brandtzaeg P (1998)
A composite DNA element in the promoter of the polymeric immunoglobulin receptor regulates its constitutive expression
Eur J Immunol, 28 (4), 1161-71
DOI 10.1002/(SICI)1521-4141(199804)28:04<1161::AID-IMMU1161>3.0.CO;2-S, PubMed 9565355

Waal H (1998)
[Is methadone a solution?]
Tidsskr Nor Laegeforen, 118 (20), 3104
PubMed 9760849

Waal H (1998)
[Is methadone effective?]
Tidsskr Nor Laegeforen, 118 (23), 3673
PubMed 9820017

Waal H (1998)
[Dogmatism on methadone]
Tidsskr Nor Laegeforen, 118 (25), 3996
PubMed 9830350

Publications 1997

Winberg JO, Hammami-Hauasli N, Nilssen O, Anton-Lamprecht I, Naylor SL, Kerbacher K, Zimmermann M, Krajci P, Gedde-Dahl T, Bruckner-Tuderman L (1997)
Modulation of disease severity of dystrophic epidermolysis bullosa by a splice site mutation in combination with a missense mutation in the COL7A1 gene
Hum Mol Genet, 6 (7), 1125-35
DOI 10.1093/hmg/6.7.1125, PubMed 9215684

Publications 1995

Brandtzaeg P, Krajci P (1995)
The enterocyte and immunoglobulin transport
Dyn.Nutr.Res., 4, 1-17

Faerden A, Waal H, Rønnow S (1995)
[Long-term psychiatric patients in a sector of Oslo]
Tidsskr Nor Laegeforen, 115 (29), 3638-41
PubMed 8539723

Kamei M, Iwase T, Krajci P, Brandtzaeg P, Moro I (1995)
Antibody production to secretory component (SC) using recombinant SC fragment
Adv Exp Med Biol, 371A, 633-5
DOI 10.1007/978-1-4615-1941-6_133, PubMed 8526006

Kulseth MA, Krajci P, Myklebost O, Rogne S (1995)
Cloning and characterization of two forms of bovine polymeric immunoglobulin receptor cDNA
DNA Cell Biol, 14 (3), 251-6
DOI 10.1089/dna.1995.14.251, PubMed 7880445

Moro I, Takahashi T, Iwase T, Asano M, Takenouchi N, Nishimura S, Kudo I, Krajci P, Brandtzaeg P, Moldoveanu Z (1995)
Expression of SC, IL-6 and TGF-beta 1 in epithelial cell lines
Adv Exp Med Biol, 371A, 175-82
DOI 10.1007/978-1-4615-1941-6_36, PubMed 8525901

Nilsen EM, Lundin KE, Krajci P, Scott H, Sollid LM, Brandtzaeg P (1995)
Gluten specific, HLA-DQ restricted T cells from coeliac mucosa produce cytokines with Th1 or Th0 profile dominated by interferon gamma
Gut, 37 (6), 766-76
DOI 10.1136/gut.37.6.766, PubMed 8537046

Norstein J, Krajci P, Bergan A, Geiran O (1995)
Intestinal perforation after ingestion of a blister-wrapped tablet
Lancet, 346 (8985), 1308
DOI 10.1016/s0140-6736(95)91918-x, PubMed 7475762

Rønnow S, Waal H (1995)
[Increasing number of involuntary emergency admissions to psychiatric institutions]
Tidsskr Nor Laegeforen, 115 (19), 2376-80
PubMed 7667852

Publications 1993

Ersland S, Kringlen E, Waal H, Thaulow JF (1993)
[Lobotomy at the Gaustad hospital]
Tidsskr Nor Laegeforen, 113 (17), 2092-5
PubMed 8337667

Publications 1992

Brandtzaeg P, Halstensen TS, Huitfeldt HS, Krajci P, Kvale D, Scott H, Thrane PS (1992)
Epithelial expression of HLA, secretory component (poly-Ig receptor), and adhesion molecules in the human alimentary tract
Ann N Y Acad Sci, 664, 157-79
DOI 10.1111/j.1749-6632.1992.tb39758.x, PubMed 1456647

BRANDTZAEG P, HALSTENSEN TS, HUITFELDT HS, KRAJCI P, KVALE D, SCOTT H, THRANE PS (1992)
EPITHELIAL EXPRESSION OF HLA, SECRETORY COMPONENT (POLY-IG RECEPTOR), AND ADHESION MOLECULES IN THE HUMAN ALIMENTARY-TRACT
Ann.NY Acad.Sci., 664, 157-179
DOI 10.1111/j.1749-6632.1992.tb39758.x

Kvale D, Krajci P, Brandtzaeg P (1992)
Expression and regulation of adhesion molecules ICAM-1 (CD54) and LFA-3 (CD58) in human intestinal epithelial cell lines
Scand J Immunol, 35 (6), 669-76
DOI 10.1111/j.1365-3083.1992.tb02973.x, PubMed 1376489

Solberg R, Sistonen P, Träskelin AL, Bérubé D, Simard J, Krajci P, Jahnsen T, de la Chapelle A (1992)
Mapping of the regulatory subunits RI beta and RII beta of cAMP-dependent protein kinase genes on human chromosome 7
Genomics, 14 (1), 63-9
DOI 10.1016/s0888-7543(05)80284-8, PubMed 1358799

Waal H (1992)
[Methadone treatment of narcotic addicts--can it be defended?]
Tidsskr Nor Laegeforen, 112 (3), 374-5
PubMed 1553680

Publications 1990

Knutsen T, Waal H (1990)
[Therapeutic and health care needs of HIV positive drug abusers. A study from an emergency institution]
Tidsskr Nor Laegeforen, 110 (22), 2861-3
PubMed 2219061

Publications 1989

Brandtzaeg P, Halstensen TS, Kett K, Krajci P, Kvale D, Rognum TO, Scott H, Sollid LM (1989)
Immunobiology and immunopathology of human gut mucosa: humoral immunity and intraepithelial lymphocytes
Gastroenterology, 97 (6), 1562-84
DOI 10.1016/0016-5085(89)90406-x, PubMed 2684725

Helgeland I, Waal H (1989)
[Can adolescents with behavioral disorders be helped? Problems among young people--behavioral disorders--preventive attempts--follow-up studies--evaluation]
Tidsskr Nor Laegeforen, 109 (14), 1509-12
PubMed 2749637

Waal H (1989)
[Buprenorphine (Temgesic)--a new agent for abuse]
Tidsskr Nor Laegeforen, 109 (12), 1326-7
PubMed 2734763

Waal H, Helgeland I (1989)
[Punishment, fostering, education and treatment. An integrated model for adolescents with behavioral disorders]
Tidsskr Nor Laegeforen, 109 (14), 1513-6
PubMed 2749638

Publications 1986

Iversen OH, Krajci P, Thoresen G (1986)
The fate of epidermal colcemid-arrested mitoses
Virchows Arch B Cell Pathol Incl Mol Pathol, 51 (2), 115-26
DOI 10.1007/BF02899022, PubMed 2873676

Publications 1983

Dahl AA, Waal H (1983)
An outcome study of primal therapy
Psychother Psychosom, 39 (3), 154-64
DOI 10.1159/000287736, PubMed 6622628

Publications 1980

Holsten F, Waal H (1980)
Evaluation of the drug taker. A step to an evaluation of treatment
Acta Psychiatr Scand Suppl, 284, 29-41
DOI 10.1111/j.1600-0447.1980.tb10428.x, PubMed 6935930

Holsten F, Waal H (1980)
The DTES - drug taking evaluation scale. A simple scale for the evaluation of drug taking behaviour
Acta Psychiatr Scand, 61 (4), 275-305
DOI 10.1111/j.1600-0447.1980.tb00582.x, PubMed 7446185

Waal H, Holsten F (1980)
Evaluation of drug taking behaviour. Some theoretical and methodological considerations
Acta Psychiatr Scand, 61 (2), 127-34
DOI 10.1111/j.1600-0447.1980.tb00572.x, PubMed 7361585

Publications 1977

Waal H (1977)
[Ward personnel in the psychiatric hospital keeper, caretaker, nurse or therapist?]
Sykepleien, 64 (18), 1019-21, 1037
PubMed 244025

Waal H (1977)
[Occupational groups and milieu therapy - various comments]
Sykepleien, 64 (20), 1144-6
PubMed 245814

Waal H (1977)
[The new sex therapy]
Tidsskr Nor Laegeforen, 97 (4), 200-2
PubMed 841552

Waal H (1977)
[Role changes for doctors, psychologists and trained social workers during structure changes at the psychiatric hospitals]
Tidsskr Nor Laegeforen, 97 (16), 846-8
PubMed 877937

Waal H (1977)
[Process- or task oriented evaluation?]
Tidsskr Nor Laegeforen, 97 (19-21), 1001-3
PubMed 898130

Waal H (1977)
[Organization and structural changes. Evaluation of open systems]
Tidsskr Nor Laegeforen, 97 (19-21), 1016-8
PubMed 898135

Waal H (1977)
[Evaluation of changes in the structure of a mental hospital]
Tidsskr Nor Laegeforen, 97 (19-21), 1035-9
PubMed 898142

Waal H, Baksaas R, Miljeteig M, Sundal N (1977)
[Team work situation in psychiatric hospital wards are changing]
Sykepleien, 64 (19), 1086-90
PubMed 244034

Publications 1973

Waal H (1973)
[Drug addiction and drug abuse in adolescence]
Tidsskr Nor Laegeforen, 93 (14), 1047-52
PubMed 4755947

Publications 1972

Waal H (1972)
[Chronic "sniffers"]
Tidsskr Nor Laegeforen, 92 (10), 701-6
PubMed 5028420

Publications 1971

Kofstad J, Boe G, Waal H (1971)
[Detection of drug abuse with thin-layer chromatography of urine]
Tidsskr Nor Laegeforen, 91 (9), 654-6
PubMed 5576180

Waal H (1971)
[The present status of adolescent drug addiction in Norway. Theoretical considerations, historical development and treatment offered]
Tidsskr Nor Laegeforen, 91 (5), 367-74
PubMed 5546519

0.19s